Atoris 20 mg - ntuziaka maka ojiji

mbadamba ihe mkpuchi

1 mbadamba ihe mkpuchi 10 mg / 20 mg nwere:
Isi
Arụ Ọrụ:
Atorvastatin calcium 10.36 mg / 20.72 mg (nke ya na atorvastatin 10.00 mg / 20.00 mg)
Ndị e mere:
povidone - K25, sodium lauryl sulfate, sọlfọ carbon, microcrystalline cellulose, lactose monohydrate, ssumum croscarmellose, magnesium stearate
N'ọbọ ihe nkiri
Opadry II HP 85F28751 White *
* Opadry II HP 85F28751 ọcha mejupụtara: polyvinyl mmanya, titanium dioxide (E171), macrogol-3000, talc

Nkọwa

Gburugburu, mbadamba biconvex dị ntakịrị, ihe mkpuchi na-acha ọcha ma ọ bụ nke na-acha ọcha.
Kink ele: acha uhie uhie ike ike uka na ịse fiimu nke na-acha ọcha ma ọ bụ fọrọ nke nta na agba.

Mlọ ọgwụ

Atorvastatin bụ ihe nnọchianya nke ahụ sitere na otu nke statins. Mainzọ kachasị mkpa nke atorvastatin bụ mgbochi nke ọrụ 3-hydroxy-3-methylglutaryl-coenzyme A - (HMG-CoA) mbelata, enzyme nke na-ejigide ntụgharị nke HMG-CoA na mevalonic acid. Mgbanwe a bụ otu n'ime ụzọ izizi na cholesterol synthesis chain n'ime ahụ.

Mmechi nke Atorvastatin nke cholesterol synthesis na - eduga n'ịbawanye ọrụ nke ndị na - anabata Lipoprotein dị nta (LDL) na imeju, yana anụ ahụ extrahepatic. Ndị na-anabata ya na-ekekọta LDL ma wepụ ha na plasma ọbara, nke na-eduga n'ịbelata mkpokọta LDL cholesterol (Ch) LDL (Ch-LDL) n'ime ọbara. Mmetụta antisclerotic nke atorvastatin bụ nsonaazụ nke nsonaazụ ya na mgbidi nke arịa ọbara na akụkụ ọbara. Atorvastatin na-egbochi njikọ nke isoprenoids, nke bụ ihe na-eto eto nke mkpụrụ ndụ dị n’ime akwara ọbara. N'okpuru mmetụta nke atorvastatin, mmụba nke endothelium na-agbatị na akwara ọbara na-emeziwanye, ntinye nke LDL-C, LDL, apolipoprotein B, triglycerides (TG) na-ebelata, na ntinye uche nke lipoprotein dị elu (HDL-C) na apolipoprotein mmụba.

Atorvastatin na-ebelata viscosity nke plasma ọbara na ọrụ nke ụfọdụ ihe coagulation na nchịkọta platelet. N'ihi nke a, ọ na - eme ka hemodynamics na - adịwanye mma ma na - edozi ọnọdụ nke coagulation system. Ndị na-egbochi HMG-CoA reductase na-emetụta metabolism nke macrophages, na-egbochi ọrụ ha ma na-egbochi nbibi nke oghere atherosclerotic.

Dịka iwu, nsonaazụ ọgwụgwọ nke atorvastatin na-etolite mgbe izu abụọ nke iji atorvastatin, a na-enwetakarị nsonaazụ kachasị mgbe izu anọ gachara.

Atorvastatin na nha nke 80 mg budata belata ihe egwu nke nsogbu nsogbu ischemic (gụnyere ọnwụ site na infarction myocardial) site na 16%, ihe ize ndụ nke ịmaliteghachi n'ụlọ ọgwụ maka angina pectoris, yana ihe ịrịba ama nke ischemia myocardial - site na 26%.

Mlọ ọgwụ

A na-enweta mmiri Atorvastatin dị elu, ihe dị ka 80% na-abanye na eriri afọ. Ogo nke nnabata na itinye uche na plasma ọbara na-abawanye na oke na nha. Oge iji ruo ịta kachasị (TCmax) bụ, na nkezi, awa 1-2. Maka ụmụ nwanyị, TCmax dị elu site na 20%, mpaghara dị n'okpuru usoro ịta oge (AUC) bụ 10% dị ala. Ọdịiche dị na ọgwụ pharmacokinetics na ndị ọrịa site na afọ na okike adịghị mkpa na ha anaghị achọ mmezi dose.

N'ime ndị ọrịa nwere ọrịa imeju na-egbu egbu, TCmax dị okpukpu iri na isii karịa elu. Iri nri nwa obere na-ebelata oke ọgwụ na oge iwere ọgwụ (site na 25% na 9%, otu ọ bụla), mana mbelata nke ịta LDL-C yiri nke ahụ na atorvastatin na-enweghị nri.

Atorvastatin bioavailability dị ala (12%), sistemụ bioavailability usoro nke inhibitory na-egbochi Htr-CoA reductase bụ 30%. Usoro bioavailability dị ala bụ n'ihi metabolism metabolism na akpụkpọ anụ mucous nke eriri afọ na "isi ihe na-agafe" site na imeju.

Nkezi ogo nke nkesa atorvastatin bụ lita 381. Ihe karịrị 98% nke atorvastatin na-ejikọ protein protein.

Atorvastatin adịghị agafe ihe mgbochi ọbara-ụbụrụ.

Ọ metabolized tumadi na imeju n'okpuru ọrụ nke ZA4 isoenzyme nke cytochrome P450 na nguzobe nke metabolites na-arụ ọrụ metabolites (ortho- na parahydroxylated metabolites, beta-oxidation ngwaahịa), nke ihe dị ka 70% nke ọrụ inhibitory megide HMG-CoA mbelata ihe karịrị awa 20-30.

Ọkara ndụ (T1 / 2) nke atorvastatin bụ awa 14. Ọ na-abụkarị ihe ana - eme ya ka ọ ghara ịdị na - eme ya ọzọ. Ihe dịka 46% nke atorvastatin bụ nke eriri afọ na-erughị 2% site na akụrụ.

Ihe ngosi maka ojiji

Ihe ngosi maka iji ọgwụ Atoris 20 mg bụ:

• Hypercholesterolemia nke mbu (heterozygous familial na hypercholesterolemia na-abụghị nke ezinụlọ (ụdị nke II dị ka Fredrickson)),
• Perdị hyperlipidemia jikọtara ọnụ (ụdị IIa na IIb dịka Fredrickson),
• Dysbetalipoproteinemia (ụdị III dịka Fredrickson) (dị ka mgbakwunye na nri),
• Familial endogenous hypertriglyceridemia (ụdị nke IV nke Fredrickson), na-eguzogide ọgwụ,
• Homozygous familial hypercholesterolemia na ezughi oke nke usoro ọgwụgwọ nri na usoro ọgwụgwọ ọgwụgwọ ndị ọzọ,

Mgbochi ọrịa obi:

• Ihe mgbochi mbu nke nsogbu obi na ndi oria n’enweghi ihe iriba ama nke akwara obi, ma otutu ihe nwere ike ito ya maka uto ya: okenye karia iri ise na ise, nicotine riri ahu, obara mgbali obara, oria obi uto, oke oria nke HDL-C n’ime plasma obara, onodu nkpuru nkpuru, tinyere megide ndabere nke dyslipidemia,
• Ihe mgbochi nke abụọ nke nsogbu obi na ọrịa obi na akwara mkpụrụ obi (CHD) iji belata mkpokọta ọnụ ọgụgụ ọgbụgba myocardial, ọrịa strok, ịmalite ụlọ ọgwụ maka angina pectoris na mkpa ịlọ ụwa.

Ihe ngbanwe

Ihe mgbochi maka iji mbadamba nkume Atoris:

• hypersensitivity na akụkụ nke ọgwụ,
• ọrịa imeju na ogbo nọ n'ọrụ (gụnyere ịba ọcha n'anya na-adịghị ala ala, ịba ọcha n'anya ịba ọcha n'anya),
• cirrhosis nke imeju nke etiology ọ bụla,
• mmụba nke transminates “imeju” nke amamịghe sitere na ya karịa ugboro atọ ma e jiri ya tụnyere oke nke ụkpụrụ,
• Ọkpụkpụ akwara
• ime na lactation,
• afọ ruo afọ 18 (edozighi ike na nchekwa nke iji ya),
• ụkọ lactase, nnagide nri nke lactose, ọrịa glucose-galactose malabsorption.

Jiri n’oge ime na inye nwa ara

Atoris nọ n'afọ ime yana mgbe a na-enye nwa ara. Nnyocha ụmụ anụmanụ na-egosi na ihe ize ndụ nke nwa ebu n’afọ nwere ike karịa uru ọ bụla ọ ga-abara nne.

N’ime ụmụ nwanyị gbara ọmụmụ, ndị na-ejighị ụzọ a pụrụ ịtụkwasị obi nke igbochi afọ ime, a gaghị akwado iji Atoris mee ihe. Mgbe ị na-eme atụmatụ ịtụrụ ime, ikwesiri ịkwụsị iji Atoris opekata mpe ọnwa 1 tupu ịtụrụ ime gị.

Onweghi ihe akaebe banyere ikenye atorvastatin nwere mmiri ara. Agbanyeghị, n'ụfọdụ ụdị anụmanụ, nchịkọta nke atorvastatin n'ọbara ọbara yana mmiri ara nke ụmụ anụmanụ na-elekọta ụmụ. Ọ bụrụ na ọ dị mkpa iji ọgwụ Atoris mee ihe n’oge a na-enye nwa ara, iji zere ihe ize ndụ nke ịmalite ihe ọjọọ na ụmụ ọhụrụ, a ga-akwụsị inye ya ara.

Usoro onunu ogwu na nhazi

Tupu ịmalite iji Atoris, a ga-ebugharị onye ọrịa na nri. na-enye mbelata ịta nke lipids n'ime ọbara, nke a ga-ahụrịrị n'oge ọgwụgwọ ya dum. Tupu ịmalite usoro ọgwụgwọ, ị kwesịrị ịgbalị iji nweta nchịkwa nke hypercholesterolemia site na mmega ahụ na oke ibu na ndị ọrịa nwere oke ibu, yana ọgwụgwọ maka ọrịa na-akpata.

A na -e oara ọgwụ ahụ ọnụ, n'agbanyeghị nri. Ọgwụ nke ọgwụ ahụ dịgasị site na 10 mg ruo 80 mg otu ugboro kwa ụbọchị ma ahọrọ họrọ iburu n'uche ntinye uche nke LDL-C, ebumnuche ọgwụgwọ na mmetụta ọgwụgwọ ọ bụla.

Enwere ike iwere Atoris otu oge n'oge ọ bụla n'ụbọchị, mana n'otu oge kwa ụbọchị.

A na-achọpụta mmetụta ọgwụgwọ ahụ ka izu abụọ nke ọgwụgwọ gasịrị, na nsonaazụ kachasị na-etolite mgbe izu anọ gachara. Ya mere, usoro onunu ogwu ekwesighi igbanwe tupu izu anọ ka mmalite nke ị inụ ọgwụ ahụ na ọgwụ gara aga.

Na mbido ọgwụgwọ na / ma ọ bụ n'oge mmụba nke dose ahụ, ọ dị mkpa iji nyochaa mmụba nke lipids na plasma ọbara kwa izu 2-4 ma dozie dose ahụ dabere.

Homozygous hereditary hypercholesterolemia

Usoro ọgwụgwọ bụ otu ihe ahụ na ụdị hyperlipidemia ndị ọzọ.

A na-ahọrọ oge izizi iche iche dabere ogo ọrịa ahụ. N'ime ọtụtụ ndị ọrịa nwere hypercholesterolemia homozygous, a na-ahụ mmetụta kachasị mma site na iji ọgwụ ahụ na ọgwụ kwa ụbọchị nke 80 mg (otu oge). A na-eji Atoris® agwọ ọrịa na usoro ọgwụgwọ ndị ọzọ (plasmapheresis) ma ọ bụ dịka ọgwụgwọ bụ isi ọ bụrụ na ọgwụgwọ na ụzọ ndị ọzọ agaghị ekwe omume.

Jiri na ndị agadi

N'ime ndị ọrịa agadi na ndị ọrịa nwere ọrịa akụrụ, a gaghị agbanwe ọgwụ Atoris. Ọrụ akụrụma anaghị arụ ọrụ emetụtaghị mkpokọta atorvastatin na plasma ọbara ma ọ bụ ogo nke Mbelata nke ịta LDL-C site na iji atorvastatin, ya mere, a chọghị ịgbanwe ọgwụ a chọrọ.

Ọrụ imeju na-arụ ọrụ

N'ime ndị ọrịa nwere ọrụ imeju na-arụ ọrụ, ọ dị mkpa ịkpachara anya (n'ihi nkwụsị nke ọgwụ iji wepụ ahụ). N'ọnọdụ dị otú a, a ga-eji nlezianya nyochaa ụlọ ọgwụ na nyocha ụlọ nyocha (ị na-ahụ maka ọrụ nke aspartate aminotransferase (ACT) na alanine aminotransferase (ALT). Site na mmụba dị ukwuu na ọrụ nke ọrịa hepatic transaminases, a ga-ebelata dose nke Atoris ma ọ bụ kwụsị ọgwụgwọ.

Nsonaazụ

Mgbe ị na-eji mbadamba 20 mg nke Atoris, mmetụta ndị nwere ike ime:

• Site na sistemụ ụjọ: ọtụtụ mgbe: isi ọwụwa, nsogbu ehighị ụra, ọgbụgbọ, paresthesia, ọrịa asthenic, adịghị ala ala: neuropathy na-emetụta ala. amnesia, hypesthesia,
• Site na akwara anụ ahụ: ugboro ugboro: tinnitus, adịkarịghị: nasopharyngitis, imi,
• Site na akụkụ ahụ na hemopoietic: nwa oge: thrombocytopenia,
• Site na sistem iku ume: oge: mgbu obi,
• Site na usoro digestive: oge: afọ ntachi, dyspepsia, ọgbụgbọ, afọ ọsịsa. flatulence (bloating), mgbu nke afọ, na enweghi oge: anorexia, uto isi, vomiting, pancreatitis, adịkarịghị: ịba ọcha n'anya, cholestatic jaundice,
• Site na usoro akwara: mgbe mgbe: myalgia, arthralgia, azụ mgbu. nkwonkwo na-esighi ike, n'oge na-adịghị anya: myopathy, nkwonkwo akwara, ọ na-esiri ike: myositis, rhabdomyolysis, tendopathy (n'ọnọdụ ụfọdụ na mgbatị anụ ahụ),
• Site na sisitemu mkpụrụ ndụ: oge ​​adịghị anya: ike nwere mbelata nke abụọ, ọdịda ezughi oke,
• N'akụkụ anụ ahụ: mgbe mgbe: ọnya ọnya, itching, ugboro ugboro: urticaria, o siri ike: angioedema, alopecia, failoma bully, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis,
• Mmeghachi omume nfụkasị: mgbe mgbe: mmeghachi omume nfụkasị ahụ, ọ na-esi ike: anaphylaxis,
• Ndị na-egosi ụlọ nyocha: ugboro ugboro: ịba ụba nke aminotransferases (ACT, ALT), ụba ọrụ nke serine creatine phosphokinase (CPK), ọ dịkarịghị: hyperglycemia, hypoglycemia,
• Ihe ozo: otutu oge: oria na aru nwa oge, oge na adighi nma: odi aru, ike ọgwụgwụ, ahua, inara ibu.
• Emebeghi mmekọrịta dị n'etiti mmetụta ụfọdụ na-adịghị mma site n'iji ọgwụ Atoris, nke a na-ewere dị ka "ihe na-adịghị ahụkebe". Ọ bụrụ na enwere mmetụta na-achọghị oke, ekwesighi ịkwụsị Atoris.

Dodoụbiga ya ókè

Achọpụtaghị ọnọdụ ịdoụbiga mmanya ókè.

N'ihe banyere ịdoụbiga mmanya ókè, ọ dị mkpa usoro ndị a dị mkpa: nleba anya na idobe ọrụ dị mkpa, yana igbochi ọzọ ị ofụ ọgwụ (eriri afọ, ị ,ụ ya ma ọ bụ ọgwụ mgbu).

Site na mmepe nke myopathy, sochiri rhabdomyolysis na nnukwu akụrụ ọdịda (mmerụ ahụ siri ike mana akụkụ siri ike), a ga-akagbu ọgwụ ahụ ozugbo yana infusion nke diuretic na sodium bicarbonate malitere. Ọ bụrụ na ọ dị mkpa, ekwesịrị ịba ahụ ụkwụ. Rhabdomyolysis nwere ike iduga hyperkalemia, nke chọrọ nchịkwa intravenous nke ihe ngwọta nke calcium chloride ma ọ bụ ihe ngwọta nke calcium gluconate, infusion nke 5% ngwọta nke dextrose (glucose) na insulin, ojiji nke resins-potassium resins, ma ọ bụ, n'ọnọdụ ndị siri ike, hemodialysis. Ọkpụkpụ anụ ahụ adịghị arụ ọrụ.

Enweghị ọgwụ mgbochi akọwapụtara.

Mkparịta ụka ọgwụ ọjọọ

Ojiji atorvastatin nwere cyclosporine, ọgwụ nje (erythromycin, clarithromycin, quinupristine / dalphopristine), ndị na-egbochi nje HIV (indinavir, ritonavir), ndị ọrụ antifungal (fluconazole, itraconazole, ketoconazole) ma ọ bụ mmịkọ bara uru. ihe egwu nke ime myopathy na rhabdomyolysis na ọdịda akwara. Yabụ, n'iji ojiji nke erythromycin TCmax atorvastatin na-abawanye site na 40%. Ọgwụ ndị a niile na-egbochi cytochrome CYP4503A4 isoenzyme, nke na-etinye aka na metabolism nke atorvastatin na imeju.

Mkparịta ụka yiri nke ahụ ga-ekwe omume na iji nke atorvastatin na-eme n'otu oge na fibrates na nicotinic acid na usoro onyalata egbugbere ọnụ (karịa 1 g kwa ụbọchị). Ojiji nke atorvastatin na onodu 40 mg na diltiazem na onwa 240 mg na-eduga na mmụba nke mkpokọta atorvastatin na plasma ọbara. Ojiji atorvastatin na-eme ihe na phenytoin, rifampicin, nke bụ ndị nọchiri anya cytochrome CYP4503A4, nwere ike ibute ịdị irè nke atorvastatin. Ebe ọ bụ na atorvastatin na-metabolized site na isoenzyme nke cytochrome CYP4503A4, ojiji nke atorvastatin n'otu oge na ndị na-egbochi cytochrome isoenzyme CYP4503A4 nwere ike ibute mmụba nke atorvastatin na plasma ọbara.

Ndị na-egbochi protein protein na-egbochi OAT31B1 (dịka ọmụmaatụ, cyclosporine) nwere ike iwelie bioavailability nke atorvastatin.

N'iji ọgwụ mgbochi oge (mgbochi nke magnesium hydroxide na aluminom hydroxide), ntinye nke atorvastatin na plasma ọbara na-ebelata.

Site na iji atorvastatin na oge nke colestipol, a na-ebelata mkpokoro atorvastatin na plasma ọbara site na 25%, mana ọgwụgwọ ọgwụgwọ nke njikọta ahụ dị elu karịa mmetụta nke atorvastatin naanị.

Ojiji atorvastatin na-ejikọ ọnụ na ọgwụ ndị na-ebelata mkpokọta homonụ steroid endogenous (gụnyere cimetidine, ketoconazole, spironolactone) na-amụba ohere nke belata homonụ steroid endogenous (ịkpachara anya kwesịrị igosipụta).

N'iji oge nke atorvastatin nwere mgbochi igbochi ọnụ (norethisterone na ethinyl estradiol), ọ ga - ekwe omume ịbawanye nnabata nke mgbochi ma mee ka itinye uche ha na plasma ọbara. Ekwesịrị inyocha nhọrọ nke ọgwụ mgbochi ime na ụmụ nwanyị na-eji atorvastatin.

Ojiji nke atorvastatin na warfarin n'oge gboo nwere ike ịbawanye uto nke warfarin na coagulation ọbara (mbelata oge prothrombin).Mmetụta a na-apụ n'anya mgbe ụbọchị iri nke ọgwụ ndị a na-eme n'otu oge.

Site na ojiji nke atorvastatin na terfenadine n'otu oge, achọpụtaghị mgbanwe dị ukwuu na ụlọ ọrụ ọgwụ nke terfenadine.

Mgbe ị na-eji atorvastatin na ndị na-ahụ maka ọgwụ mgbochi ọnụ na estrogens dị ka akụkụ nke usoro ọgwụgwọ nnọchi, enweghị akara nke mmekọrịta mmekọrịta dị oke mkpa na-achọghị.

Iji mkpụrụ osisi greepu n'oge Atoris® nwere ike ibute mmụba nke plasma nke atorvastatin. N'akụkụ a, ndị ọrịa na-a Atụ ọgwụ Atoris® kwesịrị izere ị juiceụ ihe ọ juiceụ graụ mkpụrụ osisi karịa 1.2 lita kwa ụbọchị.

Ntụziaka pụrụ iche

Mgbe ị na-ewere Atoris, ihe ize ndụ nke ịmalite myalgia na-abawanye. Ndị ọrịa kwesịrị ịnọ n'okpuru nlekọta ahụike mgbe niile. N'ọnọdụ ebe enwere mkpesa nke adịghị ike na mmepe nke mgbu olu, a na-akwụsị iji Atoris ozugbo.

Nhazi nke ọgwụ a gụnyere lactose, ekwesịrị iburu nke a n'uche na ndị ọrịa nwere enweghị lactose na ụkọ lactase.

Ekwesịrị iji ọgwụ Atoris kpachara anya na ndị ọrịa na-a fromụbiga mmanya ókè ma ọ bụrụ na akụkọ banyere imeju na-arụ ọrụ nke ọma.

N'ọnọdụ nke gosipụtara na myopathy gosipụtara, a ga-akwụsị iji Atoris kwụsị.

Atoris nwere ike itinye aka na mmepe nke ọgbụgbọ, yabụ maka oge ọgwụgwọ kwesịrị izere ịnya ụgbọ ala na ọrụ ndị chọrọ nlebara anya dị ukwuu.

Usoro ahịa ọgwụ ahịa

Atoris analogues bụ ọgwụ ndị a: Liprimar, Atorvastatin-Teva, Torvakard, Liptonorm. Ọ bụrụ na ọ dị mkpa iji họrọ onye nnọchi, a na-atụ aro ka ị buru ụzọ gwa dọkịta gị.

Ọnụ ahịa mbadamba 20 mg nke ọgwụ Atoris na ụlọ ahịa ọgwụ na Moscow bụ:

• Mbadamba 20 mg, 30 PC. - 500-550 rub.
• Mbadamba 20 mg, 90 PC. - 1100-1170 rub.

Ngwongwo ogwu

Mlọ ọgwụ
Atorvastatin bụ ihe nnọchianya nke ahụ sitere na otu nke statins. Mainzọ kachasị mkpa nke atorvastatin bụ mgbochi nke ọrụ 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) mbelata, enzyme nke na-egbochi ntụgharị nke HMG-CoA na mevalonic acid. Mgbanwe a bụ otu n'ime ụzọ izizi na cholesterol synthesis chain n'ime ahụ. Mmechi nke atorvastatin cholesterol synthesis na - eduga n'ịbawanye ọrụ nke ndị na - anabata Lipoprotein dị ala (LDL) na imeju, yana anụ ahụ extrahepatic. Ndị na-anabata ihe a na-ekekọta agbụ nke LDL ma wepụ ha na plasma ọbara, nke na-eduga n'ịbelata plasma cholesterol (Ch) LDL (Ch-LDL) na plasma ọbara.
Mmetụta antisclerotic nke atorvastatin bụ nsonaazụ nke nsonaazụ ya na mgbidi nke arịa ọbara na akụkụ ọbara. Atorvastatin na-egbochi njikọ nke isoprepoids, nke bụ ihe na-eto eto maka sel nke akwara dị n’ime akwara ọbara. N'okpuru mmetụta nke atorvastatin, mmụba nke endothelium na-eme ka akwara ọbara dịkwuo mma, itinye uche nke LDL-C, apolipyrotein B (apo-B) na-ebelata. triglycerides (TG). enwere mmụba na mkpokọta cholesterol nke lipoproteins dị elu (HDL-C) na apolipoprotein A (apo-A).
Atorvastatin na-ebelata viscosity nke plasma ọbara na ọrụ nke ụfọdụ ihe coagulation na nchịkọta platelet. N'ihi nke a, ọ na - eme ka hemodynamics na - adịwanye mma ma na - edozi ọnọdụ nke coagulation system. Ndị na-egbochi HMG-CoA reductase na-emetụta metabolism nke macrophages, na-egbochi ọrụ ha ma na-egbochi nbibi nke oghere atherosclerotic.
Dịka iwu, a na-achọpụta mmetụta ọgwụgwọ nke atorvastatin mgbe izu abụọ nke ọgwụgwọ gasịrị, mmetụta kachasị na-etolite mgbe izu anọ gachara.
Atorvastatin na nha nke 80 mg budata belata ihe egwu nke nsogbu nsogbu ischemic (gụnyere ọnwụ site na infarction myocardial) site na 16%, ihe egwu nke ịmaliteghachi n'ụlọ ọgwụ maka angina pectoris tinyere akara nke myocardial ischemia site na 26%.
Mlọ ọgwụ
A na-enweta mmiri Atorvastatin dị elu, ihe dị ka 80% na-abanye na eriri afọ. Ogosi ịnabata na itinye uche na plasma ọbara na-abawanye na oke maka osisi vaịn. Oge erute ịta kachasị (TCmax), na nkezi, awa 1-2. N'ime ụmụ nwanyị, TCmax dị elu karịa 20%, mpaghara dị n'okpuru usoro ịta ahụhụ (AUC) bụ 10% dị ala. Ọdịiche dị na ọgwụ pharmacokyetics n'ime ndị ọrịa site na afọ na okike adịghị mkpa na anaghị achọ mgbazi osisi vaịn.
N'ime ndị ọrịa nwere ọrịa imeju na-egbu egbu, TCmax dị okpukpu iri na isii karịa elu. Iri nri nwa obere na-ebelata oke ọgwụ na oge iwere ọgwụ (site na 25% na 9%, otu ọ bụla), mana mbelata nke ịta LDL-C yiri nke ahụ na atorvastatin na-enweghị nri. Atorvastatin bioavailability dị ala (12%), sistemụ bioavailability usoro nke inhibitory na-egbochi Htr-CoA reductase bụ 30%. Usoro bioavailability dị ala bụ n'ihi metabolism metabolism na akpụkpọ ahụ mucous nke eriri afọ yana “ụzọ izizi” site na umeji. Nkezi ogo nke nkesa atorvastatin bụ lita 381. Ihe karịrị 98% nke atorvastatin na-ejikọ protein protein. Atorvastatin adịghị agafe ihe mgbochi ọbara-ụbụrụ. Ọ metabolized tumadi na imeju n'okpuru ọrụ nke CYP3A4 isoenzyme na nguzobe nke pharmacologically ifịk metabolites (ortho- na parahydroxylated metabolites, beta-oxidation ngwaahịa), nke ihe ruru 70% nke ọrụ inhibitory megide HMG-CoA-mbelata ọrụ ruo 20-30 awa.
Ọkara ndụ (T1 / 2) nke atorvastatin bụ awa 14. A na - eme ya ka ọ dị nke ukwuu, ọ naghị agagharị ya mgbe a na - eme ya. Ihe dịka 46% nke atorvastatin bụ nke eriri afọ na-erughị 2% site na akụrụ.
Ndị otu ọrịa pụrụ iche
Childrenmụaka
Enwere obere data na ọmụmụ ihe emepe izu asatọ nke ọgwụ ọgwụ ụmụaka na afọ (afọ 6 ruo afọ 17) na heterozygous familial hypercholesterolemia na ntinye mbụ nke LDL cholesterol ≥4 mmol / l, mesoo na atorvastatin n'ụdị nke mbadamba nkume chewable nke 5 mg ma ọ bụ 10 mg ma ọ bụ mbadamba ihe mkpuchi dị na 10 mg ma ọ bụ 20 mg 1 oge kwa ụbọchị, karị. Naanị covariate dị mkpa na usoro ọgwụ pharmacokinetic nke ndị na-anata atorvastatin bụ ahụ. N sachapụ nke atorvastatin na ụmụaka adịghị iche na nke ndị okenye okenye, nwee ọ̀tụ̀tụ̀ allometric site na ịdị ya. N'ihe dị iche iche nke atorvastatin na o-hydroxyatorvastatin, a hụrụ mgbanwe na-agbanwe agbanwe na LDL-C na LDL.
Ndị okenye na-arịa ọrịa
Ntinye uche kachasị (Cmax) na plasma na AUC nke ọgwụ na ndị ọrịa agadi (karịa 65) bụ 40% na 30%, dị iche iche, dị elu karịa ndị ọrịa okenye. Enweghị ọdịiche dị iche na arụmọrụ yana nchekwa nke ọgwụ, ma ọ bụ na imezu ebumnuche nke ọgwụgwọ Lipid na-arịa ọrịa ndị agadi agadi ma e jiri ya tụnyere ọnụ ọgụgụ mmadụ niile.
Renrụ ọrụ na-arụ ọrụ na ụlọ
Renrụ ọrụ akụrụ na aka adịghị emetụta mkpocha atorvastatin na plasma ọbara ma ọ bụ ihe ọ na-eme na metabolism; ya mere, mgbanwe mgbanwe dose na ndị ọrịa arụ ọrụ ezughi oke ọrụ achọrọ.
Ọrụ imeju na-arụ ọrụ
Ntinye uche nke ogwu na-abawanye nke ukwuu (Cmax - ihe dị ka ugboro iri na isii, AUC - ihe dị ka ugboro 11) na ndị ọrịa nwere ọrịa cirrhosis na-egbu egbu (klas B dịka nhazi nke nwatakịrị).

Jiri n’oge ime na n’oge a na-enye nwa ara

A na-egbochi ọgwụ Atoris ® n'oge afọ ime yana n'oge a na-enye nwa ara.
Nnyocha ụmụ anụmanụ na-egosi na ihe ize ndụ nke nwa ebu n’afọ nwere ike karịa uru ọ bụla ọ ga-abara nne.
N'ime ụmụ nwanyị toro afọ ime, ndị na-ejighị ụzọ dị ịtụnanya nke igbochi afọ ime, a gaghị atụ aro iji Atoris ®. Mgbe ị na-eme atụmatụ ịtụrụ ime, ịkwesịrị ịkwụsị iji Atoris ®, opekata mpe, ọnwa 1 tupu ịtụrụ ime emee.
Onweghi ozi banyere nnabata nke atorvastatia nwere mmiri ara. Ka osi di, na ufodi umu anumanu n’oge a na-enye ara, ofta nke atorvastatia n’ime obara na mmiri ara. Ọ bụrụ n’ịchọrọ iji Atoris drug ọgwụ ahụ n’oge ị na-a breastụ ara, iji zere ihe ize ndụ nke ihe omume ndị na-adịghị mma n’ara ụmụ ọhụrụ, a ga-akwụsị inye ụmụ ya ara.

Usoro onunu ogwu na nhazi

Tupu ịmalite ị Atụ ọgwụ Atoris ®, a ga-ebugharị onye ọrịa ahụ na nri nke na -ebelata mbelata lipids na plasma ọbara, nke a ga-ahụrịrị n'oge ọgwụgwọ ya dum. Tupu ịmalite usoro ọgwụgwọ, ị kwesịrị ịgbalị iji nweta nchịkwa nke hypercholesterolemia site na mmega ahụ na oke ibu na ndị ọrịa nwere oke ibu, yana ọgwụgwọ maka ọrịa na-akpata.
A na-ewere ọgwụ ọnụ site na ọnụ, n'agbanyeghị oge nri. Ọgwụ nke ọgwụ ahụ dịgasị site na 10 mg ruo 80 mg nke m otu ugboro n’ụbọchị ma ahọrọ họrọ iburu n'uche itinye uche nke LDL-C na plasma, ebumnuche nke usoro ọgwụgwọ na mmetụta ọgwụgwọ onye ọ bụla.
Enwere ike iji Atoris ® otu oge n'oge ọ bụla n'ụbọchị, mana n'otu oge kwa ụbọchị. A na-achọpụta mmetụta ọgwụgwọ ahụ ka izu abụọ nke ọgwụgwọ gasịrị, na nsonaazụ kachasị na-etolite mgbe izu anọ gachara.
Na mbido ọgwụgwọ na / ma ọ bụ n'oge mmụba nke dose ahụ, ọ dị mkpa iji nyochaa mmụba nke lipids na plasma ọbara kwa izu 2-4 ma dozie dose ahụ dabere.
Hypercholesterolemia nke mbu yana juputara na hyperlipidemia
Maka ọtụtụ ndị ọrịa, ọgwụ a na-atụ aro nke Atoris ® bụ 10 mg otu ugboro n'ụbọchị, ọgwụgwọ ọgwụgwọ gosipụtara onwe ya n'ime izu abụọ ma na-erukarị ogo mgbe 4 pacals. Site n'ọgwụgwọ ruo ogologo oge, mmetụta ahụ na-adịgide.
Homozygous familial hypercholesterolemia
N'ọnọdụ ka ukwuu, mana a na-enye ọgwụ mg 80 mg otu ugboro kwa ụbọchị (mbelata mkpokọta LDL-C na plasma site na 18-45%).
Heterozygous familial hypercholesterolemia
Ọgwụ izizi bụ 10 mg kwa ụbọchị. Ekwesịrị ịhọrọ dose ahụ n'otu n'otu ma nyochaa mkpa nke dose ahụ kwa izu anọ na mmelite ọ nwere ike iru 40 mg kwa ụbọchị. Mgbe ahụ, enwere ike ịbawanye dose ahụ ruo ogo 80 mg kwa ụbọchị, ma ọ bụ kwe omume ijikọta usoro nke bile acid na iji atorvastatin na dose 40 mg kwa ụbọchị.
Mgbochi Ọrịa Obi
Na nyocha nke mgbochi izizi, dose oforvastatin bụ 10 mg kwa ụbọchị.
Mmụba nke dose nwere ike ịdị mkpa iji mezuo ụkpụrụ LDL-C kwekọrọ na ntuziaka ugbu a.
Jiri n'ime ụmụaka si na 10 ruo afọ 18 na heterozygous familial hypercholesterolemia
Osisi vaịn a na-atụ aro ya bụ 10 mg otu ugboro n'ụbọchị. Enwere ike ịbawanye ọgwụ ahụ ruo 20 mg kwa ụbọchị, dabere na nsonaazụ ụlọ ọgwụ. Ahụmịhe nwere ihe karịrị 20 mg (nke kwekọrọ na dose 0,5 mg / n'arọ) nwere mmachi.
Ekwesịrị ịhọrọ dose nke ọgwụ ahụ dabere na ebumnuche nke ọgwụgwọ Lipid. Ekwesịrị imeghari dose na oge nke oge 1 n'ime izu anọ ma ọ bụ karịa.
Imeju imeju
Ọ bụrụ na ọrụ imeju ezughi oke, a ga-ebelata oke nke Atoris,, yana ileba anya na ọrụ mmegharị nke “imeju”: aspartate aminotransferase (ACT) na alanine aminotransferase (ALT) na plasma ọbara.
Ọdịda ya
Ọrụ akụrụma anaghị arụ ọrụ emetụtaghị mkpokoro nke atorvastatin ma ọ bụ ogo mbelata mgbanye LDL-C na plasma, yabụ, achọrọ nhazigharị nke ọgwụ ahụ (lee mpaghara "Pharmacokinetics").
Ndị okenye na-arịa ọrịa
Enweghị ọdịiche dị iche iche na arụmọrụ ọgwụgwọ yana nchekwa nke atorvastatin na ndị ọrịa agadi etinyere na ọnụọgụ mmadụ, ọ dịghị mkpa ịgbanwe ndozi dose (lee ngalaba Pharmacokinetics).
Jiri na ọgwụ ndị ọzọ
Ọ bụrụ na ọ dị mkpa iji ya n'otu oge na cyclosporine, telaprevir, ma ọ bụ nchikota tipranavir / ritonavir, dose nke Atoris ® ekwesịghị gafere 10 mg / ụbọchị (lee akụkụ "Ntuziaka Pụrụ Iche").
Ekwesịrị iji nlezianya mee ihe yana iji ọgwụ atorvastatin dị ala kachasị mma mgbe ejiri ya na ndị na-egbochi nje HIV, nje na-egbochi ọrịa hepatitis C (boceprevir), clarithromycin na itraconazole.
Ndụmọdụ nke Russian Cardiological Society, National Society maka Ọmụmụ nke Atherosclerosis (NLA) na Russian Society of Cardiosomatic Rehabilitation na Secondary Prevention (RosOKR) (V revision 2012)
Nlekọta kachasị nke LDL-C na cholesterol zuru oke maka ndị ọrịa nwere nnukwu nsogbu bụ: ≤2.5 mmol / L (ma ọ bụ ≤100 mg / dL) na ≤4.5 mmol / L (ma ọ bụ ≤ 175 mg / dL), otu isi na maka ndị ọrịa nwere nnukwu ihe egwu: ≤1.8 mmol / l (ma ọ bụ ≤70 mg / dl) na / ma ọ bụ, ọ bụrụ na ọ gaghị ekwe omume iru, a na-atụ aro ka ịbelata mkpokọta LDL-C site na 50% site na uru mbụ na ≤4 mmol / l (ma ọ bụ ≤150 mg / dl), n'otu n'otu.

Mmetụta akụkụ

Nkewa di iche-iche nke nmekorita nke World Health Organisation (WHO):